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QS-21 shows in vitro hemolytic effect and causes side effects in vivo. New saponin adjuvant
formulations with better toxicity profiles are needed. This study aims to evaluate the safety
and tolerability of QS-21 and the improved saponin adjuvants (ISCOM, ISCOMATRIX and
Matrix-M™) from vaccine trials.
Methods
A systematic literature search was conducted from MEDLINE, EMBASE, Cochrane library
and Clinicaltrials.gov. We selected for the meta-analysis randomized controlled trials
(RCTs) of vaccines adjuvanted with QS-21, ISCOM, ISCOMATRIX or Matrix-M™, which
included a placebo control group and reported safety outcomes. Pooled risk ratios (RRs)
and their 95% confidence intervals (CIs) were calculated using a random-effects model.
Jadad scale was used to assess the study quality.
Results
Nine RCTs were eligible for the meta-analysis: six trials on QS-21-adjuvanted vaccines and
three trials on ISCOMATRIX-adjuvanted, with 907 patients in total. There were no studies
on ISCOM or Matrix-M™ adjuvanted vaccines matching the inclusion criteria. Meta-analysis
identified an increased risk for diarrhea in patients receiving QS21-adjuvanted vaccines
(RR 2.55, 95% CI 1.04–6.24). No increase in the incidence of the reported systemic AEs
was observed for ISCOMATRIX-adjuvanted vaccines. QS-21- and ISCOMATRIX-adju-
vanted vaccines caused a significantly higher incidence of injection site pain (RR 4.11, 95%
CI 1.10–15.35 and RR 2.55, 95% CI 1.41–4.59, respectively). ISCOMATRIX-adjuvanted
vaccines also increased the incidence of injection site swelling (RR 3.43, 95% CI 1.08–
10.97).
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Conclusions
Our findings suggest that vaccines adjuvanted with either QS-21 or ISCOMATRIX posed no
specific safety concern. Furthermore, our results indicate that the use of ISCOMATRIX
enables a better systemic tolerability profile when compared to the use of QS-21. However,
no better local tolerance was observed for ISCOMATRIX-adjuvanted vaccines in immu-
nized non-healthy subjects. This meta-analysis is limited by the relatively small number of
individuals recruited in the included trials, especially in the control groups.
Introduction
Adjuvants are substances that do not confer immunity on their own [1]. However, when added
to immunogens, they facilitate, improve and maintain the immune responses against the
immunogens [2,3]. Therefore, adjuvants provide a rational strategy to improve the efficacy of
vaccines, especially in the case of weak immunogens and/or vaccines intended for individuals
with weakened immune systems (e.g. newborns, the elderly or immune-compromised per-
sons). Furthermore, adjuvants allow for dose sparing of vaccine antigen and helps in reducing
the cost of vaccination programs [4,5].
A group of immunoenhancers of great interest is saponins, whose strong adjuvant activity
was first described in 1930s [6]. Saponins are natural triterpenoid or steroid glycosides, which
can be extracted from the bark of a South American tree Quillaja saponaria (Soapbark) [7,8].
QS-21 is one of the most potent and the most extensively studied saponin adjuvants in numer-
ous studies including prophylactic and therapeutic vaccines for both animals and humans
[9,10]. QS-21 has been shown to be an effective immunological adjuvant for human vaccines
with a wide variety of antigens and to have a relatively low toxicity in preclinical studies in
mice [11,12]. It stimulates both antibody and cellular immune responses composed of both
Th1 and Th2 immunity. The cellular immune stimulating capacity of QS-21 is especially
important for developing vaccines against cancers and intracellular pathogens [13]. A number
of vaccine trials have been performed using QS-21 as adjuvant, initially for cancer vaccines (i.e.
melanoma, breast and prostate cancer) and, subsequently, for vaccines against Alzheimer’s dis-
ease and infectious diseases, including human immunodeficiency virus (HIV)-1, influenza,
herpes simplex virus (HSV), malaria and hepatitis B diseases [9,12].
However, the natural saponin QS-21 has inherent disadvantages such as chemical instabil-
ity, limited supply, difficult and low-yielding purification, and dose-limiting toxicity, which
prevent it from wider use [14]. Importantly, QS-21 could cause hemolysis in vitro and its use in
vivo has been observed with side effects [7]. Saponins have been shown to interact with choles-
terol, and might form pores in the lipid bilayer of cell membranes. When such interaction hap-
pens to erythrocytes, hemolysis could occur [15].
In order to reduce saponin-related toxicity, the formulation of immunostimulating complex
(ISCOM) was developed by Morein et al. in 1984 [16]. ISCOMs are open cage-like 40-nm par-
ticulate structures, which are formed spontaneously if cholesterol, phospholipids, saponin and
viral envelope proteins are mixed together [17,18]. The formulation retains the adjuvant activ-
ity of the saponin with an increased stability, when compared to QS-21. Furthermore, the con-
cern of hemolysis is solved by eliminating the possibility of the saponin to interact with cell
membranes [19,20]. Nevertheless, the types of antigens that can be incorporated into ISCOM
are restricted, and the incorporation process is difficult to control [4].
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Due to these technical problems and the fact that antigen incorporation is not necessary to
achieve a potent immune stimulation, matrix formulations such as ISCOMATRIX and Matrix-
M™ were developed. These matrix formulations contain the same components and have the
same structure as the ISCOM but without the incorporated antigen [19,21]. ISCOMATRIX
usually contains Quil A or more purified forms of saponins, including QS-21, ISCOPREP™ 703
and, more recently, ISCOPREP [22]. Matrix-M™ is a combination of two individually formed
matrix particles from different purified fractions of Quillaia saponins, namely Matrix-A™ and
Matrix-C™ [23]. The former fraction has a higher adjuvant activity while the latter fraction has
a lower adjuvant activity but a high tolerance [19].
Both ISCOMATRIX and Matrix-M™ adjuvanted vaccines have been tested in animal models
and more recently in human clinical trials [19,22,23]. Vaccines adjuvanted with either ISCO-
MATRIX or Matrix-M™ have been shown to induce strong antibody and T-cell responses and
to be well tolerated in both pre-clinical and clinical studies [24,25]. ISCOMATRIX is currently
under evaluation in candidate vaccines against hepatitis C virus (HCV) [26], influenza [27]
and cancer [28–30]. Matrix-M™ is currently being investigated in vaccines for influenza, HSV
type 2 and malaria [23,31]. Current applications of ISCOMs include the development of influ-
enza vaccines for humans [32].
The benefits from adjuvant incorporation into any vaccine formulation have to be balanced
with the risk of adverse events (AEs) [2]. The purpose of this meta-analysis is to evaluate the
safety and tolerability of QS-21 and the improved saponin-based adjuvants such as ISCOMA-
TRIX. Here we focus on single adjuvant formulations (QS-21, ISCOM, ISCOMATRIX and
Matrix-M™) rather than combinations of adjuvants. Therefore, studies that used adjuvant sys-
tems, such as AS01, AS02 and AS04 developed by GlaxoSmithKline, were not included in the
analysis.
Methods
We conducted a meta-analysis according to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement [33]. The protocol for the study was not pub-
lished online.
Literature search strategy
A systematic search of literature was performed using the electronic databases of MEDLINE
(Ovid), EMBASE and Cochrane Central register of Controlled Trials (CENTRAL). The clinical
trial register (clinicaltrials.gov) was searched for unpublished trials. To define the studies of
interest in these databases, the following keywords were used: “QS-21”, “ISCOMs”, “ISCOMA-
TRIX”, “Matrix-M”, “randomized controlled trial” and “clinical trial”. Details of the search
strategy are provided in the supporting information (S1 Appendix). References were imported
to RefWorks where duplicate entries were removed. Furthermore, the literature search was
complemented by manual search of the reference lists of all identified studies and reviews for
additional studies.
Study selection
References were evaluated using the pre-defined inclusion criteria: (1) randomized controlled
trials (RCTs) on vaccines with saponin adjuvants (QS-21, ISCOM, ISCOMATRIX or Matrix-
M™); (2) which included a control group (i.e., individuals immunized with saline buffer, adju-
vant alone, antigen alone or adjuvanted with a licensed adjuvant); and (3) reporting informa-
tion regarding safety and/or tolerability. The inclusion of only RCT studies was considered
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necessary to avoid the possible selection and reporting biases that may arise from observational
studies.
Two independent reviewers (EB, ED) performed primary evaluation of the retrieved articles
for relevance based on the title and abstract. Disagreements were discussed with a third investi-
gator (HL) until consensus was achieved. Potentially eligible publications were reviewed as full
text. The acronym PICOS (patients, interventions, comparator (control) group, outcomes and
study design) was used to assess if the references fully complied with the inclusion criteria. In
order to lower the between-study heterogeneity and due to the fact that there were not enough
eligible RCTs in healthy volunteers to be included for the meta-analysis, we limited our study
selection to RCTs that recruited adult (18 years and older) non-healthy subjects. References for
which full-text could not be acquired electronically or were reported not in English language
were excluded.
Data extraction
Two independent reviewers (EB and ED) identified potentially relevant articles and collected
the following data: the first author’s last name, the year of publication, clinicaltrials.gov identi-
fier (if applicable), study design, total number of participants, age range, gender, disease back-
ground, study arms with number of vaccinated participants in each arm, doses of adjuvants
used for the preparation of vaccines, immunization route and number of injections.
The following safety outcomes were identified from the included studies and considered for
the meta-analysis: serious, systemic and local AEs. The commonly reported systemic AEs
across the selected studies included headache, fatigue, insomnia, pyrexia, myalgia, nausea, diar-
rhea, dizziness, anxiety and back pain. The local AEs included injection site pain, redness, ery-
thema and swelling.
Evaluation of study quality
Following Cochrane guidelines for systematic reviews of interventions [34], two independent
reviewers (EB, ED) assessed the quality of individual studies included in the meta-analysis. The
Jadad scale for reporting RCTs, which summarizes the methodological quality of a study in an
overall score, was employed. In brief, the Jadad scale evaluates three items: randomization (up
to two points are given), double blinding (up to two points are given) and report of withdrawals
and dropouts (up to one point is given). An overall score between zero and five is assigned. A
score of three and above is commonly regarded as the reference point for adequate trial quality
[35]. Studies were not to be excluded on the basis of this assessment but their quality scores
were taken into account when describing results.
Data analysis
To evaluate the safety and tolerability of saponin adjuvanted vaccines, the dichotomous data
on the number of subjects experiencing a systemic or local AE in the saponin-adjuvanted study
vaccine group and placebo group were extracted from each study with subsequent determina-
tion of the risk ratios (RR) and their 95% confidence intervals (CI). Of note, within each study
we pooled all subjects that received adjuvanted vaccine, regardless the concentration of the
adjuvant and antigen in vaccine formulation. We combined data statistically using random
effects (Mantel-Haenszel method) model due the differences in among the studies in e.g. vac-
cine formulation, adjuvant dose and the disease background of subjects. Chi2 and I2 statistics
were used to assess the heterogeneity among the included studies. Values of I2 can be inter-
preted as low (25–50%), moderate (50–75%), and high (75% and greater) levels of heterogene-
ity [36]. Meta-analyses were performed using Review Manager (RevMan 5.3, Cochrane
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Collaboration). Results were considered to be statistically significant with a p value of<0.05. In
addition to the meta-analysis, descriptive reports on serious adverse events (SAEs) and treat-
ment discontinuations were given.
Dealing with missing data
Our analysis relies solely on the existing data.
Assessment of reporting biases
Due to the limited number of studies available for meta-analysis, assessment of publication
bias was not applicable. The review is subject to publication bias.
Results
Search results
A total of 813 references were identified from electronic databases during the search performed
during 03–04.03.2016 (Fig 1). Additional 7 references were identified by manual search. After
removing duplicate entries (151), 669 references were evaluated for inclusion based on the title
and/or abstract. As a result, 112 potentially relevant articles were included in the next stage
for the full-text evaluation. From the 112 articles, full text was unavailable for 13 studies, 3
references were reviews, and 1 reference was a completed clinical trial with no study results
reported. Characteristics of the study population, interventions, control groups, the evaluated
outcomes and/or design of the study (PICOS) did not meet the inclusion criteria in 81 publica-
tions. Most of these studies did not include a control group, i.e. all enrolled subjects received
the saponin-adjuvanted vaccines. One meta-analysis [37] and four pooled analyses [22,38–40]
were excluded since the original safety data of the reported studies were not retrievable. Ulti-
mately, a total of nine RCTs fulfilled all inclusion criteria and were selected for the meta-analy-
sis [41–49].
Study characteristics
The main characteristics of the selected RCTs are summarized in Table 1. Among nine studies,
six used QS-21 and three used ISCOMATRIX as vaccine adjuvant. No RCTs on ISCOM or
Matrix-M™ adjuvanted vaccines matched the inclusion criteria. Briefly, the trials on ISCOM
(one trial) and Matrix-M™ (one trial [50], two reports [51,52]) adjuvanted vaccines were per-
formed in healthy volunteers and/or did not report safety data.
The six trials on QS-21-adjuvanted vaccines enrolled a total of 755 individuals, of which 510
in the treatment group (i.e. subjects received antigen with adjuvant) and 245 in the control
groups (i.e. subjects received placebo, antigen alone or adjuvant alone). A total of 152 non-
healthy subjects were recruited for the three RCTs on ISCOMATRIX-adjuvanted vaccines and
included 98 and 54 in the treatment and control groups, respectively. The selected trials for
both adjuvants recruited adult non-healthy subjects. Studies that involved healthy volunteers
could not be included for the meta-analysis due to the limited number of identified studies that
fulfilled the pre-defined inclusion criteria. The age of the enrolled subjects in the nine studies
varied from 19 to 85 years, among which 44.9% were males.
All studies reported the number of subjects experiencing a specific AE. Studies of Anderson
et al. [47] and Frazer et al. [48] used a seven-day diary card to record specific local and systemic
AEs. In the former study, unsolicited AEs could also be reported on a separate 30-day diary
card. In the study of Frazer et al. [48], an additional home visit was conducted with each study
subject at the end of the follow-up period. Studies described by Gilman et al. [41] and Wald
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et al. [42] did not mention the method of AE reporting; however, they used physical examina-
tions and evaluations of clinical and laboratory parameters after each vaccination. In the
Sharp&Corp study [49], the safety data was collected up to 4 years after first dose of vaccine
by systematic assessment (not further specified). During Pfizer studies NCT00479557 [43]
and NCT00498602 [44] AEs were reported throughout 110 weeks, including a 6-week screen-
ing period, 52 weeks of dosing and 54 weeks for follow-up after the last dose. The studies
NCT00752232 [45] and NCT01227564 [46] recorded AEs from day 1 throughout the trial
Fig 1. Flowchart of the evaluation and inclusion process for the meta-analysis. From: Moher D, Liberati A, Tetzlaff J,
Altman DG, The PRISMAGroup (2009). Preferred Reporting Iterns for Systematic Reviews andMeta-Analyses: The
PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097 For more information, visit www.
prisma-statement.org.
doi:10.1371/journal.pone.0154757.g001
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Table 1. Characteristics of the included studies.










Gilman et al, 2005 372 50–85 167:205 AD Arm1: AN1792 225 μg + QS-
21 (n = 300)
50 μg IM/6 [41]
Arm2: Placebo (n = 72)
Wald et al, 2011 35 21–54 11:24 HSV-2 Arm1: HerpV 80 μg + QS-21
(n = 7)
50 μg SC/3 [42]
Arm2: HerpV 240 μg + QS-21
(n = 6)
Arm3: HerpV 80 μg (n = 6)
Arm4: HerpV 240 μg (n = 6)
Arm5: QS-21 (n = 5)
Arm6: Placebo (n = 5)
Pﬁzer, 2014# 245 60–78 106:139 AD Arm1: ACC-001 3 μg + QS-21
(n = 36)
50 μg IM/5 [43,44]
(NCT00479557) (86) Arm2: ACC-001 10 μg + QS-
21 (n = 61)
(NCT00498602) (159) Arm3: ACC-001 30 μg + QS-
21 (n = 40)
Arm4: ACC-001 10 μg (n = 35)
Arm5: ACC-001 30 μg (n = 12)
Arm6: QS-21 50 μg (n = 44)
Arm7: Placebo (n = 17)
Pﬁzer, 2014 (a) 40 62–77 17:23 AD Arm1: ACC-001 3 μg + QS-21
(n = 6)
50 μg IM/5 [45]
(NCT00752232) Arm2: ACC-001 10 μg (n = 6)
Arm3: ACC-001 10 μg + QS-
21 (n = 6)
Arm4: ACC-001 30 μg (n = 6)
Arm5: ACC-001 30 μg + QS-
21 (n = 6)
Arm6: QS-21 50 μg (n = 6)
Arm7: Placebo (n = 4)
Pﬁzer, 2015 63 61–75 30:33 AD Arm1: ACC-001 3 μg + QS-21
(n = 22)
50 μg IM/6 [46]
(NCT01227564) Arm2: ACC-001 10 μg + QS-
21 (n = 20)




35 35–58 35:0 HIV Arm1: HPV16 E6E7 25 μg
+ IMX (n = 4)
120 μg IM/3 [47]
Arm2: HPV16 E6E7 70 μg
+ IMX (n = 8)
Arm3: HPV16 E6E7 240 μg
+ IMX (n = 8)
Arm4: HPV16 E6E7 240 μg
+ IMX (n = 8)
Arm5: Placebo (n = 7)
Frazer et al, 2004 31 19–57 0:31 CIN Arm1: HPV16 E6E7 20 μg
+ IMX (n = 9)
100 μg IM/3 or 1 [48]
(Continued)
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(24 months and 104 weeks, respectively). All Pfizer studies used non-systematic assessment of
AEs. Furthermore, trials NCT00479557, NCT00498602, NCT01227564 and Sharp&Corp (but
not NCT00752232) used 5% frequency threshold for reporting AEs (not including SAEs). A
threshold of 5% indicates that only AEs with a frequency greater than 5% within at least one
arm were reported.
Study quality
The methodological quality of the included RCTs was satisfying (Table 2), except for the study
fromWald et al. [42] According to the Jadad scale, eight out of the nine studies (88.8%) have a
score of 3 or 4. The study published by Wald et al. [42] has a score of 2 due to the fact that this
RCT was single-blinded, and there was insufficient information on the randomization method.
QS-21-adjuvanted vaccine versus placebo
Serious adverse events (SAEs). Wald et al. [42] reported no SAEs related to any treat-
ment. On the other hand, treatment-related SAEs including encephalitis, encephalopathy, con-
fusion, grand mal convulsion, retinal vein thrombosis, cerebral hemorrhage and hemiplegia
were reported by Gilman et al [41]. The SAEs were observed in 7.3% (95% CI 4.9–10.8%) of
QS-21-adjuvanted vaccine recipients and in 0% (95% CI 0–5%) of placebo recipients. This
Table 1. (Continued)









Arm2: HPV16 E6E7 60 μg
+ IMX (n = 10)
Arm3: HPV16 E6E7 200 μg
+ IMX (n = 5)
Arm4: Placebo (n = 7)
Sharp & Corp,
2012
86 65–84 41:45 AD Arm1: V950 0.5 μg + IMX
16 μg (n = 8)
16, 47 or IM/3 [49]
(NCT00464334) Arm2: V950 5 μg + IMX 16 μg
(n = 8)
94 μg*
Arm3: V950 50 μg + IMX 16 μg
(n = 8)
Arm4: V950 0.5 μg + IMX
47 μg (n = 7)
Arm5: V950 5 μg + IMX 47 μg
(n = 8)
Arm6: V950 0.5 μg + IMX
94 μg (n = 7)
Arm7: V950 0.5 μg (n = 8)
Arm8: V950 5 μg (n = 9)
Arm9: V950 50 μg (n = 5)
Arm10: IMX 16 μg (n = 13)
Arm11: Placebo (n = 5)
*We included in our meta-analysis all intervention study arms (arm1-6), for which individuals received vaccines containing ISCOMATRIX (16, 47 or 94 μg)
for a larger sample size.
#We combined two clinical trials sponsored by Pﬁzer (NCT00479557 and NCT00498602) since only pooled data from these two studies were disclosed.
Abbreviations: M, male; F, female; HIV, Human Immunodeﬁciency Virus; CIN, Cervical Intraepithelial Neoplasia; AD, Alzheimer’s Disease; HSV-2,
genital Herpes Simplex Virus type 2; IMX, ISCOMATRIX; IM, Intramuscular; SC, Subcutaneously.
doi:10.1371/journal.pone.0154757.t001
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clinical trial was discontinued because of severe AEs, mostly associated with encephalitis. All
subjects who reported meningoencephalitis received QS-21-adjuvanted vaccine. Deaths
occurred during the follow-up period of the trial, however, with a similar incidence rate in the
QS-21-adjuvanted vaccine group (1.7%, 95% CI 0.7–3.9%) and the placebo group (2.8%, 95%
CI 0.8–9.6%). Of note, deaths in QS-21-adjuvanted vaccine group were caused by myocardial
infarction, broken neck, progression of AD, or non-hemorrhagic cerebral infarct; whereas
deaths in the placebo group were caused by neoplasm or cerebral hemorrhage.
All Pfizer studies [43–46] reported on SAEs. The SAEs incidence rate observed in the QS-
21-adjuvanted vaccine groups was similar across the four trials (Pfizer 2014: 17.7%, 95% CI
12.2–24.9%; Pfizer 2014(a): 11.1%, 95% CI 3.1–32.1%; Pfizer 2015: 16.7%, 95% CI 8.3–30.6%).
Furthermore, three out of four trials [43,44,46] showed that SAEs occurred with the similar or
higher frequency in the placebo group (Pfizer 2014: 17.7%, 95% CI 6.2–41.0%; Pfizer 2015:
28.6%, 95% CI 13.8–49.9%). In contrast, Pfizer 2014(a) trial [45] reported no SAEs in the pla-
cebo group (0%, 95% CI 0–48.9%). The most common SAEs across the four Pfizer studies
were: confusion, hallucinations, syncope, urinary tract infection, cardiac arrest, chest pain and
hypotension. The pooled data from two Pfizer 2014 trials [43,44] indicated one case of death in
the QS-21-adjuvanted vaccine group (the cause was not further specified). No deaths occurred
during Pfizer 2014(a) and 2015 trials [45,46].
Systemic adverse events. The most frequent systemic AEs observed across the six studies
include headache, fatigue, insomnia, pyrexia, nausea, diarrhea, dizziness, anxiety and back
pain. The results of the meta-analysis demonstrated that out of the nine systemic AEs selected
for the analysis, only cases of diarrhea were significantly more frequent in non-healthy subjects
receiving QS-21-adjuvanted vaccines than in those receiving placebo (pooled RR 2.55, 95% CI
1.04–6.24, p = 0.04) (Fig 2). Furthermore, although the pooled RRs did not reach statistical sig-
nificance, a trend towards a higher incidence of headache was observed in the QS-21-adju-
vanted vaccine group (pooled RR 1.66, 95% CI 0.93–2.97, p = 0.09). Aside from the systemic
AEs included in the meta-analysis, other commonly reported systemic AEs ( 5% of partici-
pants) were vomiting, myalgia, asthenia, upper respiratory tract infection, urinary tract infec-
tion, constipation, contusion and nasopharyngitis.
Local adverse events. Regarding the local AEs, we were not able to retrieve dichotomous
data from RCT reported by Gilman et al. [41] However, the authors mentioned that injection

















Described as randomized* 1 1 1 1 1 1 1 1
Described as double-blind* 1 0 1 1 1 1 # 1# 1
Description of withdrawals* 0 1 1 1 1 1 1 1
Randomization method
described and appropriate**
1 0 0 0 0 1 -1 0
Double-blinding method
described and appropriate**
0 0 0 0 0 0 1 0
Score 3 2 3 3 3 4 3 3
* A study receives a score of 1 for “yes” and 0 for “no”
** A study receives a score of 0 if no description is given, 1 if the method is described and appropriate, and -1 if the method is described but
inappropriate.
# The word “double-blind” was not used by the authors. However, according to the description of the blinding of the investigator, investigational site staff,
and participants, one point was given for “described as double-blind”.
doi:10.1371/journal.pone.0154757.t002
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Fig 2. Meta-analysis of the reported systemic adverse events observed in non-healthy subjects
receiving QS-21-adjuvanted vaccines or placebo.
doi:10.1371/journal.pone.0154757.g002
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site reactions were reported in both QS-21-adjuvanted vaccine group and placebo group, and
the reported cases tended to be more severe and of longer duration among subjects treated
with QS-21-adjuvanted vaccine. Furthermore, Pfizer 2015 trial [46] was not included in the
meta-analysis on local AEs due to the fact that the only reported local AEs were injection site
hematoma (7.1%, 95% CI 2.5–19.0% in QS-21-adjuvanted vaccine group; 0%, 95% CI 0–15.5%
in placebo group) and injection site pruritus (4.8%, 95% CI 1.3–15.8% in QS-21-adjuvanted
vaccine group; 0%, 95% CI 0–15.5% in placebo group).
The meta-analysis showed that QS-21-adjuvanted vaccines caused significantly more cases
of injection site pain (pooled RR 4.11, 95% CI 1.10–15.35, p = 0.04) than placebo (Fig 3). No
statistically significant increase in the risk for injection site redness/erythema and injection site
swelling was observed with the immunization with QS-21-adjuvanted vaccines.
Discontinuations due to AEs. Together with SAEs, systemic and local AEs, we were inter-
ested in the cases of discontinuations due to the AEs. Wald et al. [42] reported that two subjects
(5.7%, 95% CI 1.6–18.6%) dropped out form the study due to AEs that occurred in a temporal
relation with the QS-21-adjuvanted vaccine. One subject developed severe arthralgia, and
another developed mild neck pain and neck vein distention. The number of subjects who dis-
continued treatment due to AEs could not be retrieved from the study of Gilman et al [41].
However, the authors stated that the AEs leading to treatment discontinuations were more fre-
quent among the participants receiving QS-21-adjuvanted vaccine than those receiving pla-
cebo. The two Pfizer 2014 trials [43,44] resulted in 4 dropouts in QS-21-adjuvanted vaccine
group (2.9%, 95% CI 1.2–7.3%) due to the AEs related to the study vaccine with no cases of
discontinuation in the placebo group (0%, 95% CI 0–18.4%). Furthermore, other 4 subjects
Fig 3. Meta-analysis of the reported local adverse events observed in non-healthy subjects receiving QS-21-adjuvanted vaccines or
placebo.
doi:10.1371/journal.pone.0154757.g003
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discontinued the treatment in QS-21-adjuvanted vaccine group due to the AEs unrelated to the
study vaccine. The AEs that caused discontinuation were not specified. No withdrawals due
to AEs were reported from the Pfizer 2014(a) trial [45]. In general, these three trials showed
higher incidence of discontinuations in the QS-21-adjuvanted vaccine group compared to the
placebo. Pfizer 2015 trial [46] resulted in one case of discontinuation due to the AEs in QS-
21-adjuvanted vaccine group and no cases in the placebo group. However, the total incidence
of dropouts in Pfizer 2015 trial was twice higher in placebo group (28.6%, 95% CI 13.8–49.9%)
than in QS-21-adjuvanted vaccine group (14.3%, 95% CI 6.7–27.9%).
ISCOMATRIX-adjuvanted vaccine versus placebo
Serious adverse events. Studies of Anderson et al. [47] and Frazer et al. [48] reported no
SAEs in ISCOMATRIX-adjuvanted vaccine recipients. The study from Sharp&Corp [49]
detected SAEs in both treatment and control groups, and the observed SAEs included syncope,
transient ischemic attack, squamous cell carcinoma of skin, and contusion. SAEs occurred in
19.6% (95% CI 10.7–33.2%) and 20% (95% CI 3.6–62.0%) of the recipients of the tested vaccine
containing ISCOMATRIX and placebo, respectively. The same study reported a SAEs rate of
31.8% (95% CI 16.4–52.7%) in subjects who received only the antigen, and 0% (95% CI
0–22.8%) in those received only adjuvant (i.e. 16 μg ISCOMATRIX).
Systemic adverse events. The most commonly reported systemic AEs across the selected
studies include headache, fatigue, pyrexia, nausea, myalgia and insomnia. In general, the
observed systemic AEs were mild to moderate in severity and lasted for 2–3 days. The propor-
tion of subjects reporting systemic AEs was greater in the ISCOMATRIX-adjuvanted vaccine
group than in the placebo group. The meta-analysis comparing the incidence of systemic AEs
between the ISCOMATRIX adjuvanted vaccine group and placebo group showed no statisti-
cally significant differences in any selected for the analysis systemic AE (Fig 4). Furthermore,
pooled RRs were generally lower for ISCOMATRIX-adjuvanted vaccines than for vaccines
containing QS-21.
Local adverse events. The reported local AEs were usually associated with injection site
pain, redness/erythema and swelling. Individual studies reported also other local AEs such as
warmth, bruising, injection site hematoma and injection site pruritus. Trials of Anderson et al.
[47] and Frazer et al. [48] specified that the proportion of subjects experiencing an injection
site reaction (including pain, swelling, warmth, redness and bruising) or injection site pain was
greater in the groups receiving ISCOMATRIX-adjuvanted vaccines than in the group of sub-
jects receiving placebo. In general, the observed local AEs were of mild to moderate intensity.
The meta-analysis showed that there was no association between the exposure to the ISCOMA-
TRIX-adjuvanted vaccines and the incidence of local redness/erythema (pooled RR 1.87, 95%
CI 0.76–4.61). However, the ISCOMATRIX-adjuvanted vaccines significantly increased the
likelihood of experiencing the injection site pain (pooled RR 2.55, 95% CI 1.41–4.59, p = 0.002)
and swelling (pooled RR 3.43, 95% CI 1.08–10.97, p = 0.04) than placebo (Fig 5). Of note, the
risk for injection site pain is approximately 1,6 times less for subjects receiving ISCOMATRIX-
adjuvanted vaccines compared to subjects receiving QS-21-adjuvanted vaccines (pooled RR
2.55 vs. pooled RR 4.11). In contrast, the risk for injection site swelling increases two-fold in
subjects receiving ISCOMATRIX-adjuvanted vaccines (pooled RR 3.43 vs. pooled RR 1.75).
Discontinuations due to AEs. Anderson et al. [47] reported that no participants withdrew
due to the AEs. Frazer et al. [48] reported that three women who received ISCOMATRIX-adju-
vanted vaccine did not complete the treatment because of AEs (12.5%, 95% CI 4.3–31%). The
AEs that caused discontinuation were not specified. Besides, no discontinuation in the placebo
group (0%, 95% CI 0–35%) was reported from the same study. Sharp&Corp [49] reported that
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Fig 4. Meta-analysis of the reported systemic adverse events observed in non-healthy subjects receiving ISCOMATRIX-adjuvanted
vaccines or placebo.
doi:10.1371/journal.pone.0154757.g004
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15.2% (95% CI 7.6–28.2%) subjects who received vaccine adjuvanted with ISCOMATRIX, 0%
(95% CI 0–22.8%) subjects who received 16 μg ISCOMATRIX alone and 0% (95% CI 0–43.4%)
subjects who received placebo discontinued the study due to the AEs (AEs not specified). Simi-
lar to what we observed from the QS-21-adjuvanted vaccine trials, more individuals in the
ISCOMATRIX-adjuvanted vaccine group discontinued the treatment compared to the placebo
group.
Saponin-adjuvanted vaccine versus placebo
In order to study the general effect of saponin adjuvantation on the safety and tolerability of
tested vaccines, we performed meta-analysis on the reported AEs from all nine eligible studies.
In the case of frequently reported systemic AEs, we were able to combine the dichotomous
data on the number of non-healthy subjects experiencing headache, fatigue, insomnia, pyrexia,
myalgia, nausea, diarrhea, dizziness, anxiety and back pain after immunization with QS-21- or
ISCOMATRIX-adjuvanted vaccines (Fig 6). The meta-analysis showed that there was a trend
towards a higher risk of systemic AEs in patients receiving saponin-adjuvanted vaccine com-
pared to those receiving placebo, although the difference was not statistically significant (e.g.
headache: pooled RR 1.36, 95% CI 0.95–1.93, p = 0.09; diarrhea: pooled RR 2.32, 95% CI 0.99–
5.45, p = 0.05).
When combining the data on the frequently reported local AEs from all selected trials, the
performed meta-analysis confirmed that immunization of non-healthy subjects with saponin-
adjuvanted vaccines increased the risk for injection site pain (pooled RR 2.76, 95% CI 1.61–4.73,
Fig 5. Meta-analysis of the reported local adverse events observed in non-healthy subjects receiving ISCOMATRIX-adjuvanted vaccines
or placebo.
doi:10.1371/journal.pone.0154757.g005
Meta-Analysis on Vaccines with QS-21 or ISCOMATRIX Adjuvant
PLOS ONE | DOI:10.1371/journal.pone.0154757 May 5, 2016 14 / 22
p = 0.0002) and injection site swelling (pooled RR 2.62, 95% CI 1.07–6.45, p = 0.04), when com-
pared to placebo (Fig 7). Furthermore, the results showed a trend towards an increased risk for
injection site redness/erythema in patients receiving saponin-adjuvanted vaccine compared to
those receiving placebo, although it was not statistically significant (pooled RR 1.44, 95% CI
0.95–2.17, p = 0.08).
Discussion
The objective of this meta-analysis was to assess the safety and tolerability of vaccines contain-
ing QS-21 and new saponin adjuvant formulations such as ISCOM and ISCOMATRIX. Refer-
ences were included if they reported on a RCT of vaccines with saponin adjuvants (QS-21,
ISCOM, ISCOMATRIX, or Matrix-M™) including a placebo control group and reporting infor-
mation regarding safety and/or tolerability. The effect of saponin-adjuvantation was evaluated
by the RR with 95% CI for systemic and local AEs. Reports on SAEs and the number of subjects
who discontinued treatment due to the AEs were discussed descriptively. We identified three
studies reported on ISCOMATRIX-adjuvanted vaccines and six studies on vaccines adjuvanted
with QS-21. All nine studies included adult ( 18 years) non-healthy subjects. Overall, we
included in the meta-analysis 98 subjects receiving ISCOMATRIX-adjuvanted vaccines, 510
Fig 6. Meta-analysis of the reported systemic adverse events observed in non-health subjects receiving saponin-adjuvanted vaccines or
placebo.
doi:10.1371/journal.pone.0154757.g006
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subjects receiving QS-21-adjuvanted vaccines and 138 receiving placebo. Eight of the nine trials
have a Jadad score of 3 or 4 indicating an adequate trial quality.
SAEs were reported by five studies [41,43–46] on QS-21-adjuvanted vaccines and one
study on vaccines adjuvanted with ISCOMATRIX (Sharp&Corp [49]). However, none of the
observed SAEs were considered to be related to the use of the saponin adjuvants. The majority
of SAE cases described by Gilman et al. [41] were associated with encephalitis. The authors
linked the addition of polysorbate-80 to the vaccine formulation with the occurrence of the
SAEs. Polysorbate-80 is an emulsifier that helps to improve the product stability, and was pre-
viously shown to be involved in the development of the inflammatory reaction. According to
Gilman et al. [41], the addition of polysorbate-80 may have caused a greater exposure of anti-
genic epitopes, which might lead to an inflammatory T-cell response. All reported cases of
encephalitis occurred mainly in the antibody non-responders and are reviewed in detail by
Orgogozo et al [53]. Of note, none of four Pfizer trials in subjects with Alzheimer’s disease
observed any cases of encephalitis. The SAEs reported by Sharp&Corp [49] were unlikely asso-
ciated with the use of ISCOMATRIX as an adjuvant due to the fact that SAEs were not more
frequent in the recipients of ISCOMATRIX-adjuvanted vaccine compared to those received
placebo or the antigen alone.
Fig 7. Meta-analysis of the local adverse events observed in non-healthy subjects receiving saponin-adjuvanted vaccines or placebo.
doi:10.1371/journal.pone.0154757.g007
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Based on the performed meta-analysis, none of the reported systemic AEs were significantly
increased upon the administration of ISCOMATRIX-adjuvanted vaccines. In the case of QS-
21-adjuvanted vaccines, patients experienced significantly more cases of diarrhea compared to
placebo. Most of the systemic AEs observed across the included studies were of mild to moder-
ate intensity and of short duration. When we combined the systemic AEs from all the selected
studies to evaluate the general effect of saponin adjuvantation on the safety and tolerability of
the tested vaccines, we observed that none of the frequently reported systemic AEs were signifi-
cantly increased upon the use of saponin-adjuvanted vaccines. In general, the relative risks of
the reported systemic AEs from the pooled saponin studies are higher than those observed
from the ISCOMATRIX-specific studies, but lower than those observed from the QS-21-spe-
cific studies.
The performed meta-analysis further showed that both QS-21- and ISCOMATRIX-adju-
vanted vaccines are associated with a higher risk for injection site pain, although the estimated
risk is twice lower for ISCOMATRIX-adjuvanted vaccines. On the other hand, the risk for
injection site swelling is only increased upon the use of the vaccines containing ISCOMA-
TRIX-adjuvanted vaccines. Although the use of QS-21-adjuvanted vaccines also resulted in a
trend towards a higher risk for injection site swelling, the risk was not statistically significant
and was 1.6 times less when compared to ISCOMATRIX-adjuvanted vaccines. When we
pooled the data on reported local AEs from all selected trials, the meta-analysis confirmed that
the use of saponin-adjuvanted vaccines significantly increased the likelihood of experiencing
both injection site pain and swelling. This might provide a possible reason for the observation
that generally more treatment discontinuations due to the AEs were reported from the sapo-
nin-adjuvanted vaccine recipients than control group.
The safety and tolerability profile of QS-21- and ISCOMATRIX-adjuvanted vaccines
revealed by the performed meta-analysis in non-healthy subjects is similar to that observed in
healthy volunteers. In healthy subjects, no vaccine related SAEs were observed receiving QS-
21- or ISCOMATRIX-adjuvanted vaccines [26,39,54,55]. However, these trials conducted in
healthy subjects often reported higher incidence of systemic AEs in saponin-adjuvanted vac-
cine study group than in placebo or an active control group. The systemic AEs reported in
healthy subjects were mild to moderate in intensity, self-limiting and of short duration. Local
AEs observed in healthy volunteers included local pain, redness and induration. The injection
site pain was often moderate to severe and was more frequently reported by QS-21-adjuvanted
vaccine recipients than those receiving placebo [54,55]. The study of Waite et al. [40] further
confirmed that the presence of QS-21 in the injected formulation is associated with the injec-
tion site pain. Interestingly, McKenzie et al. [39] stated that the incidence of local and systemic
AEs using ISCOMATRIX vaccines is similar to that published for other adjuvanted vaccines
(e.g., AS04, aluminum containing adjuvant).
The selected RCTs aimed to assess not only the safety and tolerability of the study vaccines,
but also the immunogenicity. To be able to determine the added immunogenicity value of an
adjuvant, we need to compare the immune responses elicited by the adjuvanted study vaccines
with non-adjuvanted vaccines (i.e. antigen-adjuvant vs. antigen alone). Only one out of three
trials on ISCOMATRIX-adjuvanted vaccines [49] and four out of six trials on QS-21-adju-
vanted vaccines [42–45] included appropriate study groups. Moreover, the high heterogeneity
in immune parameters reported by different trials, such as the immune factors analyzed (i.e.
antibody responses or cellular immune responses), the assays performed (i.e. enzyme-linked
immunosorbent assay (ELISA) or enzyme-linked immunospot (ELISPOT)), the units used
(i.e. geometric mean titer or mean fold-increase of a specific antibody response) and the time-
frame of the analysis restrains us from performing meta-analysis on the immunological benefit
of saponin adjuvants. However, the immune boosting effect of saponin adjuvants can be
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confirmed by the data reported from five of the selected trials [42–45,49]. One should consider
that the immunological benefit of the saponin adjuvants should be weighed against the poten-
tial risk of adverse events. The significant increase in the incidence of injection site pain and
swelling upon the immunization with saponin-adjuvanted vaccines might prevent the use of
such adjuvants in routine immunizations, especially in the case of prophylactic vaccines.
The results of the meta-analysis should be interpreted with caution due to the several limita-
tions. To have direct information about the safety and tolerability of adjuvants, the adjuvanted
test vaccines should be compared to an active control group (immunization with the antigen
alone or antigen with licensed adjuvants). Although there were five eligible RCTs [42–
45,56,57] on QS-21-adjuvanted vaccines with an active control group (antigen alone), we iden-
tified only one eligible RCT on ISCOMATRIX-adjuvanted vaccine [49]. Due to the limitation,
AEs reported from the saponin-adjuvant vaccine group were compared with those from the
placebo group in our meta-analysis, which made the actual causes of AEs associated with the
use of saponin-adjuvanted vaccines unidentifiable. In addition, the number of the included
clinical trials meeting the inclusion criteria was limited. Furthermore, the number of subjects
recruited to each of these trials was generally small, especially for the control groups. These
contribute to the wide confidence intervals, and decrease the statistical power to detect statisti-
cally significant differences between the treatment groups. Due to the different settings of the
trials included in the meta-analysis, we chose random-effects model for the meta-analysis,
which further widens the confidence intervals. Last but not least, differences in the reporting
method of observed AEs and the classification of AEs limit the possibility for including respec-
tively more trials for the meta-analysis or perform meta-analysis on other reported AEs among
the included studies.
Conclusions
No major safety concern was identified for both ISCOMATRIX-adjuvanted vaccines and vac-
cines containing QS-21 based on the reported SAEs. Most AEs reported by non-healthy sub-
jects in the nine selected trials were generally mild to moderate, self-limiting and of short
duration. The performed meta-analysis showed that the use of QS-21-adjuvanted vaccines
resulted in a statistically significant increase in the incidence of diarrhea when compared to
placebo, while no systemic AEs were found to be associated with the use of ISCOMATRIX-
adjuvanted vaccines. Both QS-21- and ISCOMATRIX-adjuvanted vaccines were associated
with a higher incidence of injection site pain. The observed elevated risk for local pain was
lower for the vaccines containing ISCOMATRIX. On the other hand, an increased incidence of
injection site swelling was only observed from the use of ISCOMATRIX-adjuvanted vaccines.
Furthermore, the pooled analysis on ISCOMATRIX- and QS-21-adjuvanted vaccines further
confirmed that subjects receiving a saponin-adjuvanted vaccine experienced significantly more
injection site pain and swelling when compared to placebo. In addition, for both adjuvants the
number of subjects who discontinued treatment was higher in the group of subjects receiving
the adjuvanted vaccine than in the placebo group. Our results indicate that the use of ISCO-
MATRIX results in a better systemic tolerability profile when compared to the use of QS-21.
However, no better local tolerance was observed for ISCOMATRIX-adjuvanted vaccines in
immunized non-healthy subjects. The relatively small number of published studies, however,
limited our ability to calculate robust estimates for other AEs and to draw strong conclusions
on the effects of QS-21- and ISCOMATRIX-adjuvanted vaccines. Therefore, further studies
are needed, particularly with properly defined and reported safety outcomes and including an
active control group, to better evaluate the risks of saponin adjuvanted vaccines.
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